Shots:
- Skye Bioscience has partnered with Arecor Therapeutics to develop a higher concentration formulation of Skye’s nimacimab, leveraging Arecor’s Arestat formulation platform
- As per the deal, Skye will fund Arecor’s development efforts, with the option to license rights of the new proprietary formulation & its intellectual property for further development & commercialization
- Nimacimab (CB1 inhibitor, QW, t½: 18-21 days) is being investigated in P-IIa (Cbeyond) trial in overweight & obese pts, with initial 26wk. treatment period data expected by either late Q3 or early Q4’25
Ref: Globenewswire| Image: Skye Bioscience & Arecor Therapeutics| Press Release
Related News:- Novo Nordisk Enters a ~$2.2B Deal with Septerna to Develop Oral Small Molecules for Cardiometabolic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
